HGEN - Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19

Under the umbrella of Operation Warp Speed, Humanigen (HGEN) and a joint program unit within the U.S. Department Defense will collaborate with the Department of Health and Human Services' BARDA to develop lenzilumab, a monoclonal antibody designed to prevent and treat a potentially life-threatening hyperimmune response called cytokine storm, for emergency use during the COVID-19 pandemic.Management will host a conference call this morning at 9:00 am ET to discuss the agreement.Shares up 7% premmarket on modest volume.

For further details see:

Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19